A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
GSK PLC operates in the Drug Manufacturers - General industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 44.3B | 44.3B | 41.0B | 37.9B | 36.1B | 33.9B |
| Net Income | 7.5B | 7.5B | 3.3B | 6.2B | 19.3B | 7.0B |
| EPS | $1.83 | $1.83 | $0.80 | $1.50 | $1.35 | $1.12 |
| Free Cash Flow | 9.8B | 9.8B | 8.1B | 8.1B | 7.7B | 9.6B |
| ROIC | 21.6% | 22.4% | 10.6% | 16.7% | 12.0% | 8.4% |
| Gross Margin | 70.5% | 70.5% | 69.7% | 71.8% | 67.4% | 66.9% |
| Debt/Equity | 1.08 | 1.08 | 1.24 | 1.96 | 2.70 | 1.60 |
| Dividends/Share | $0.84 | $0.84 | $0.77 | $0.69 | $0.30 | $0.89 |
| Operating Income | 10.5B | 10.5B | 5.1B | 8.4B | 7.9B | 6.0B |
| Operating Margin | 23.6% | 23.6% | 12.6% | 22.2% | 21.9% | 17.6% |
| ROE | 34.9% | 38.6% | 19.7% | 43.3% | 92.2% | 24.9% |
| Shares Outstanding | 4,051M | 4,051M | 4,074M | 4,053M | 14,098M | 6,147M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 43.1B | 31.4B | 33.9B | 36.1B | 37.9B | 41.0B | 44.3B | 44.3B |
| Gross Margin | 64.9% | 67.4% | 66.9% | 67.4% | 71.8% | 69.7% | 70.5% | 70.5% |
| R&D | 5.8B | 6.2B | 6.9B | 6.8B | 7.8B | 8.2B | 9.9B | 9.9B |
| SG&A | 14.6B | 9.6B | 9.7B | 10.3B | 11.7B | 14.1B | 12.0B | 12.0B |
| EBIT | 8.9B | 7.7B | 6.0B | 7.9B | 8.4B | 5.1B | 10.5B | 10.5B |
| Op. Margin | 20.6% | 24.6% | 17.6% | 21.9% | 22.2% | 12.6% | 23.6% | 23.6% |
| Net Income | 6.7B | 8.2B | 7.0B | 19.3B | 6.2B | 3.3B | 7.5B | 7.5B |
| Net Margin | 15.6% | 26.2% | 20.6% | 53.3% | 16.2% | 8.0% | 17.0% | 17.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | 41.0% | 17.9% | 8.4% | 12.0% | 16.7% | 10.6% | 22.4% | 21.6% |
| ROE | 28.7% | 32.8% | 24.9% | 92.2% | 43.3% | 19.7% | 38.6% | 34.9% |
| ROA | N/A | 7.9% | 6.6% | 21.1% | 8.3% | 4.4% | 9.6% | 9.4% |
| Cash Flow | ||||||||
| Op. Cash Flow | 10.2B | 10.9B | 10.9B | 9.1B | 8.4B | 8.4B | 10.2B | 10.2B |
| Free Cash Flow | 8.6B | 9.6B | 9.6B | 7.7B | 8.1B | 8.1B | 9.8B | 9.8B |
| Owner Earnings | 10.2B | 10.9B | 10.9B | 9.1B | 8.4B | 8.4B | 10.2B | 10.2B |
| CapEx | 1.6B | 1.3B | 1.3B | 1.4B | 354M | 235M | 382M | 382M |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 382M |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | 15.8% | 11.7% | 11.9% | 15.4% | 4.2% | 2.8% | 3.7% | 3.7% |
| Capital Allocation | ||||||||
| Dividends Paid | 5.0B | 5.1B | 5.5B | 4.3B | 2.8B | 3.1B | 3.4B | 3.4B |
| Dividend Yield | 4.3% | 4.9% | 4.6% | 1.6% | 3.9% | 3.8% | 4.2% | 3.9% |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 1.8B | 1.8B |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.8% | 2.1% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | 40.2B | 41.0B | 29.0B | 27.7B | 16.8B | 18.9B | 18.9B |
| Cash & Equiv. | 6.0B | 8.1B | 5.9B | 4.6B | 3.7B | 5.0B | 4.5B | 4.5B |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | 18.7B | 19.4B | 19.4B |
| Debt/Equity | N/A | 1.80 | 1.60 | 2.70 | 1.96 | 1.24 | 1.08 | 1.08 |
| Interest Coverage | 7.6 | 6.8 | 5.7 | 7.3 | 8.5 | 6.0 | 11.3 | 11.3 |
| Equity | 23.4B | 26.8B | 29.3B | 12.4B | 16.0B | 17.5B | 21.6B | 21.6B |
| Total Assets | N/A | 103.7B | 108.7B | 74.1B | 73.6B | 76.1B | 80.7B | 80.7B |
| Total Liabilities | N/A | 76.8B | 79.4B | 61.7B | 57.7B | 59.3B | 59.6B | 59.6B |
| Intangibles | N/A | N/A | N/A | N/A | N/A | 19.8B | 22.1B | 22.1B |
| Retained Earnings | N/A | 8.7B | 10.9B | 5.4B | 9.0B | 10.0B | 13.5B | 13.5B |
| Working Capital | N/A | -2.5B | -6.9B | -2.5B | -3.0B | -6.0B | -5.1B | -5.1B |
| Current Assets | N/A | 26.1B | 25.7B | 25.6B | 23.3B | 21.7B | 23.1B | 23.1B |
| Current Liabilities | N/A | 28.5B | 32.5B | 28.1B | 26.3B | 27.8B | 28.2B | 28.2B |
| Per Share Data | ||||||||
| EPS | 1.18 | 1.56 | 1.12 | 1.35 | 1.50 | 0.80 | 1.83 | 1.83 |
| Owner EPS | 1.83 | 2.08 | 1.78 | 0.65 | 2.08 | 2.06 | 2.52 | 2.52 |
| Book Value | 4.18 | 5.14 | 4.77 | 0.88 | 3.94 | 4.29 | 5.34 | 5.34 |
| Cash Flow/Share | 1.83 | 2.08 | 1.78 | 0.65 | 2.08 | 2.06 | 2.52 | 1.86 |
| Dividends/Share | 0.90 | 0.98 | 0.89 | 0.30 | 0.69 | 0.77 | 0.84 | 0.84 |
| Shares Out. | 5.6B | 5.2B | 6.1B | 14.1B | 4.1B | 4.1B | 4.1B | 4.1B |
| Valuation | ||||||||
| P/E Ratio | 20.3 | 11.7 | 19.5 | 13.1 | 12.3 | 20.8 | 13.4 | 11.8 |
| P/FCF | 15.6 | 9.9 | 14.0 | 32.1 | 9.2 | 8.3 | 10.1 | 8.9 |
| EV/EBIT | N/A | 17.6 | 29.4 | 34.9 | 12.2 | 16.4 | 11.3 | 10.2 |
| Price/Book | 5.7 | 3.6 | 4.6 | 19.9 | 4.7 | 3.9 | 4.6 | 4.1 |
| Price/Sales | 3.1 | 3.0 | 4.0 | 6.9 | 2.0 | 1.6 | 2.2 | 2.0 |
| FCF Yield | 6.4% | 10.1% | 7.1% | 3.1% | 10.8% | 12.1% | 9.9% | 11.2% |
| Market Cap | 134.8B | 95.5B | 134.9B | 247.8B | 74.8B | 67.5B | 99.4B | 87.9B |
| Avg. Price | 20.90 | 20.07 | 19.50 | 19.42 | 17.79 | 20.12 | 19.73 | 21.70 |
| Year-End Price | 24.03 | 18.30 | 21.95 | 17.58 | 18.47 | 16.56 | 24.54 | 21.70 |
GSK PLC passes 4 of 9 quality checks, suggesting mixed fundamentals.
GSK PLC trades at 11.8x trailing earnings, compared to its 15-year median P/E of 13.4x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 8.9x vs a median of 10.1x. The company's 5-year average ROIC is 14.0% with a gross margin of 69.3%. Total shareholder yield (dividends + buybacks) is 5.9%. At current prices, the estimated annualized return to fair value is -0.5%.
GSK PLC (GSK-L) has a current P/E ratio of 11.8, compared to its historical median P/E of 13.4. The stock is currently considered Fair based on its historical valuation range.
GSK PLC (GSK-L) has a 5-year average return on invested capital (ROIC) of 14.0%. This indicates solid capital allocation.
GSK PLC (GSK-L) has a market capitalization of $87.9B. It is classified as a large-cap stock.
Yes, GSK PLC (GSK-L) pays a dividend with a trailing twelve-month yield of 3.85%. The company also returns capital through share buybacks, with a buyback yield of 2.07%.
Based on historical P/E analysis, GSK PLC (GSK-L) appears fair. The current P/E of 11.8 is 12% below its historical median of 13.4. The estimated fair value CAGR (P/E method) is -3.9%.
GSK PLC (GSK-L) operates in the Drug Manufacturers - General industry, within the Healthcare sector.
GSK PLC (GSK-L) reported annual revenue of $44.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
GSK PLC (GSK-L) has a net profit margin of 17.0%. This is a healthy margin.
GSK PLC (GSK-L) generated $9.8 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
GSK PLC (GSK-L) has a debt-to-equity ratio of 1.08. This indicates moderate leverage.
GSK PLC (GSK-L) reported earnings per share (EPS) of $1.83 in its most recent fiscal year.
GSK PLC (GSK-L) has a return on equity (ROE) of 38.6%. This indicates the company generates strong returns for shareholders.
GSK PLC (GSK-L) has a 5-year average gross margin of 69.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for GSK PLC (GSK-L), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
GSK PLC (GSK-L) has a book value per share of $5.34, based on its most recent annual SEC filing.